Pemigatinib (Pemazyre) is a targeted therapy indicated for the treatment of specific types of cholangiocarcinoma and myeloid/lymphoid neoplasms (MLN) with FGFR1 rearrangement.

Adverse Reactions of Pemigatinib (Pemazyre)

Common Adverse Reactions in Cholangiocarcinoma Patients

Hyperphosphatemia (60%).

Alopecia (49%).

Diarrhea (47%).

Nail toxicity (43%).

Dysgeusia (40%).

Adverse Reactions in Patients with Myeloid/Lymphoid Neoplasms

Hyperphosphatemia (74%).

Nail toxicity (62%).

Alopecia (59%).

Stomatitis (53%).

Diarrhea (50%).

Severe Adverse Reactions of Pemigatinib (Pemazyre)

Retinal Pigment Epithelial Detachment (RPED)

This is a severe ocular adverse reaction requiring special attention.

A comprehensive ophthalmologic examination, including Optical Coherence Tomography (OCT), must be performed before the initiation of treatment.

Repeat examinations every 2 months for the first 6 months, then every 3 months thereafter.

Seek emergency medical care immediately if visual symptoms such as blurred vision, floaters, or photopsia occur.

Hyperphosphatemia and Soft Tissue Calcification

Hyperphosphatemia confirmed by laboratory tests occurs in 93% of patients.

33% of patients require phosphate-lowering treatment.

Initiate a low-phosphorus diet when serum phosphorus level exceeds 5.5 mg/dL.

Start phosphate-lowering treatment when serum phosphorus level exceeds 7 mg/dL.

Temporary interruption, dose reduction, or permanent discontinuation of the drug may be necessary if needed.

Precautions for Pemigatinib (Pemazyre)

Drug Interactions

Avoid concomitant use with strong and moderate CYP3A inducers.

If co-administration with a strong or moderate CYP3A inhibitor is unavoidable, the dose of pemigatinib should be reduced.

Patients of Childbearing Potential

Verify pregnancy status before the start of treatment.

Effective contraceptive measures must be adopted.

Be aware of the potential risks of the drug passing through the placental barrier.

Correct Administration Method

Swallow the tablets whole; do not crush, chew, split, or dissolve them.

Take the medication at approximately the same time each day, with or without food.

If a dose is missed by more than 4 hours or vomiting occurs after administration, skip the missed dose and take the next scheduled regular dose.